See more : ROBOTIS Co., Ltd. (108490.KQ) Income Statement Analysis – Financial Results
Complete financial analysis of NatureWise Biotech & Medicals Corporation (4732.TWO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of NatureWise Biotech & Medicals Corporation, a leading company in the Biotechnology industry within the Healthcare sector.
- China National Electric Apparatus Research Institute Co., Ltd. (688128.SS) Income Statement Analysis – Financial Results
- Shibuya Corporation (SHKBF) Income Statement Analysis – Financial Results
- e-Seikatsu Co.,Ltd. (3796.T) Income Statement Analysis – Financial Results
- AAEON Technology Inc. (6579.TW) Income Statement Analysis – Financial Results
- China Life Insurance Company Limited (2628.HK) Income Statement Analysis – Financial Results
NatureWise Biotech & Medicals Corporation (4732.TWO)
About NatureWise Biotech & Medicals Corporation
NatureWise Biotech & Medicals Corporation engages in the development of therapeutic drugs in Taiwan. It offers LipoCol Forte, a capsule for hypercholesterolemia and hypertriglyceridemia; PPL Taiwan green propolis; and NBM-BMX, an oral softgel capsule to treat cancer. The company was founded in 2000 and is based in Taipei, Taiwan.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 160.14M | 228.59M | 249.80M | 306.92M | 307.47M | 108.48M | 69.10M | 57.53M |
| Cost of Revenue | 72.76M | 109.60M | 114.91M | 135.54M | 146.27M | 58.21M | 39.45M | 34.17M |
| Gross Profit | 87.38M | 118.99M | 134.90M | 171.38M | 161.20M | 50.27M | 29.65M | 23.36M |
| Gross Profit Ratio | 54.56% | 52.05% | 54.00% | 55.84% | 52.43% | 46.34% | 42.91% | 40.60% |
| Research & Development | 30.01M | 43.53M | 63.60M | 62.39M | 78.19M | 31.67M | 52.40M | 55.32M |
| General & Administrative | 36.34M | 34.45M | 31.12M | 36.43M | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 17.60M | 19.61M | 18.63M | 20.97M | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 53.94M | 49.12M | 44.32M | 51.08M | 50.12M | 40.38M | 37.20M | 34.32M |
| Other Expenses | 0.00 | 106.00K | 1.71M | -870.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 83.95M | 92.64M | 107.92M | 113.46M | 128.32M | 72.05M | 89.60M | 89.64M |
| Cost & Expenses | 156.71M | 202.24M | 222.82M | 249.00M | 274.58M | 130.26M | 129.05M | 123.81M |
| Interest Income | 5.96M | 3.61M | 1.98M | 2.34M | 1.02M | 1.72M | 2.09M | 3.31M |
| Interest Expense | 52.00K | 40.00K | 32.00K | 58.00K | 60.00K | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 10.42M | 10.94M | 11.29M | 12.05M | 11.56M | 7.94M | 4.36M | 2.67M |
| EBITDA | 20.39M | 37.29M | 38.27M | 69.97M | 54.69M | -8.02M | -55.59M | -63.61M |
| EBITDA Ratio | 12.73% | 16.31% | 15.32% | 22.80% | 14.45% | -12.75% | -80.45% | -110.56% |
| Operating Income | 3.43M | 26.35M | 26.98M | 57.92M | 32.88M | -21.78M | -59.95M | -66.28M |
| Operating Income Ratio | 2.14% | 11.53% | 10.80% | 18.87% | 10.69% | -20.08% | -86.76% | -115.21% |
| Total Other Income/Expenses | 6.49M | 3.68M | 3.66M | 1.41M | 10.19M | 5.82M | -1.50M | 8.21M |
| Income Before Tax | 9.92M | 30.02M | 30.64M | 59.33M | 43.07M | -15.96M | -61.45M | -58.07M |
| Income Before Tax Ratio | 6.20% | 13.13% | 12.27% | 19.33% | 14.01% | -14.71% | -88.93% | -100.93% |
| Income Tax Expense | -196.00K | 0.00 | -168.00K | -5.98M | 3.37M | -1.15M | -960.00K | 1.94M |
| Net Income | 10.12M | 30.02M | 30.81M | 65.32M | 39.70M | -14.82M | -60.49M | -60.01M |
| Net Income Ratio | 6.32% | 13.13% | 12.33% | 21.28% | 12.91% | -13.66% | -87.54% | -104.31% |
| EPS | 0.20 | 0.61 | 0.63 | 1.33 | 1.05 | -0.39 | -1.58 | -1.57 |
| EPS Diluted | 0.20 | 0.61 | 0.62 | 1.32 | 1.05 | -0.39 | -1.58 | -1.57 |
| Weighted Avg Shares Out | 50.60M | 49.29M | 49.29M | 49.29M | 37.80M | 38.23M | 38.23M | 38.23M |
| Weighted Avg Shares Out (Dil) | 49.91M | 49.49M | 49.34M | 49.37M | 37.80M | 38.23M | 38.23M | 38.23M |
Source: https://incomestatements.info
Category: Stock Reports